National Centre for
Pharmacoeconomics
NCPE Ireland
About Us
Current Staff
News
Glossary
Contact Us
Vacancies
Home
Submission Process
HTA Guidelines
Process Flowchart
Submission Templates
Pharmacoeconomic Evaluations
Drugs
Vaccines
Diagnostics and Other Technologies
Publications
Peer Reviewed Papers
Abstracts
Reports
Research
Pharmacoeconomic Research
Education
COVID-19
For Patients
Latest Drugs
Difelikefalin (Kapruvia®). HTA ID: 23001 -
February 2, 2023
Olaparib (Lynparza®) in combination with bevacizumab (1L maintenance HRD positive ovarian cancer). HTA ID: 21011 -
January 27, 2023
Tixagevimab/cilgavimab (Evusheld®). HTA ID: 22074 -
January 25, 2023
Estriol (Blissel®) 50 micrograms per gram. HTA ID: 22071 -
January 23, 2023
Drospirenone/estetrol monohydrate (Drovelis®). HTA ID: 22073 -
January 23, 2023
Oral Azacitidine (Onureg®). HTA ID: 22070 -
December 23, 2022
Eladocagene exuparvovec (UpstazaTM). HTA ID: 22072 -
December 23, 2022
Tixagevimab /cilgavimab (Evusheld®). HTA ID: 22015 -
December 21, 2022
Pembrolizumab (Keytruda®) for oesphageal carcinoma or HER-2 negative gastroesophageal junction adenocarcinoma . HTA ID: 21032 -
December 21, 2022
Amikacin Sulfate (Arikayce® liposomal nebuliser dispersion). HTA ID: 20048 -
December 20, 2022
1
2
3
4
5
6
7
8
9
10
...
20
30
40
...
Next Page
Last »
health check
©2023 National Centre for Pharmacoeconomics
